PipelineReview.com - Biotech News & Online Store - Abiomed Receives FDA Approval Of The Abiocor®, The World's First Completely Self-Contained, Implantable Artificial Heart

Abiomed Receives FDA Approval Of The Abiocor®, The World's First Completely Self-Contained, Implantable Artificial Heart

06 Sep 2006

Announced today it has received Humanitarian Device Exemption (HDE) approval from the U.S. Food and Drug Administration (FDA) for its AbioCor® Implantable Replacement Heart (AbioCor).

DENVERS, MA, USA | Sep 05, 2006 | Abiomed, Inc. (NASDAQ: ABMD) announced today it has received Humanitarian Device

Exemption (HDE) approval from the U.S. Food and Drug Administration (FDA) for its AbioCor® Implantable Replacement Heart (AbioCor). This landmark approval will provide patients suffering from heart failure on both sides of their heart (bi-ventricular) and who have no other alternative, a viable option for extending the quality of their life. The AbioCor is the first completely self-contained artificial heart that may allow patients more time at home, without wires or tubes piercing through their skin. This technology provides patients with complete mobility and remote diagnostics.

According to the American Heart Association’s 2006 Statistics, each year 57,000 patients in the United States die from chronic heart failure. While roughly 2,200 donor hearts are transplanted into patients suffering from heart failure, there are many more patients awaiting a second chance at life, for whom a heart transplant is not an option. Patients with advanced age, organ failure or cancer are, in most circumstances, ineligible for a heart transplant and are potential candidates to receive the AbioCor implantable heart. The Humanitarian Device Exemption (HDE) approval of the AbioCor signifies that no comparable alternative therapy exists for patients facing imminent death without the technology, and that it has proven to be safe and have probable benefit for patients.

“FDA approval of the AbioCor provides new hope for heart failure patients who cannot recover their natural heart or receive a transplant. Abiomed has been a leader in recovering patients’ hearts following an acute event and with this approval, we have expanded our product portfolio to treat patients with chronic heart failure as well,” said Michael R. Minogue, Chairman, CEO and President of Abiomed. “We are pleased with this landmark decision and extremely proud of the extensive efforts of our employees, scientists, numerous healthcare professionals, FDA staff and individuals and families who have been actively involved in the clinical study of the AbioCor to advance the future of medical technology.”

“This is a momentous day for Abiomed and for all the key contributors to the development and advancement of the AbioCor. In 1964, the National Heart Institute (NHI), now the National Heart, Lung and Blood Institute (NHLBI), created its Artificial Heart Program to reduce death and disability from heart disease through the development of reliable cardiac assist and total replacement heart systems. Today marks the realization of that mission, which Abiomed has worked towards since the company’s founding in 1981,” said Robert T.V. Kung, Ph.D., Chief Scientific Officer and Senior Vice President of Abiomed. Dr. Kung led the evolution of the Abiocor technology over the past 25 years.

The AbioCor is intended to replace the severely damaged native heart for patients who are not eligible for a transplant and have no other treatment alternative. The AbioCor sustains the body’s circulatory system and is designed to extend the lives of patients who would otherwise die of heart failure, while also offering a probable benefit for a satisfactory quality of life. A post-market study is planned to allow Abiomed to monitor and optimize the introduction of the AbioCor into clinical use.

The FDA decision was completed after extensive review of the clinical testing, beginning with clinical trials starting in 2001 under an Investigational Device Exemption (IDE). The AbioCor would be available under an HDE to a limited patient population in the United States under this approval, with no more than 4,000 patients receiving the technology each year. In order to ensure the highest standards of patient care, Abiomed intends to make the AbioCor available through a controlled roll-out at approximately five to ten heart hospitals in the United States, including qualified clinical trial sites and additional qualified centers once they have completed a comprehensive and rigorous training program which may take six to eight months. Under HDE approval, the FDA may request a panel review of the post-approval study data. In addition, Abiomed is working with the Centers for Medicare and Medicaid Services (CMS) and private insurers to establish reimbursement policies for the AbioCor.

Jewish Hospital in Louisville, KY, an AbioCor clinical trial site, will be among the first U.S. hospitals to offer patients the AbioCor. The Jewish Hospital/University of Louisville team, led by surgeons Laman Gray, M.D., and Rob Dowling, M.D., performed the first and second AbioCor implantable replacement heart procedures in the world and a total of seven implants since 2001. Two other hospitals are entering into a letter of intent. They are: The Johns Hopkins Hospital in Baltimore, MD, with Dr. John Conte, and Robert Wood Johnson University Hospital in New Brunswick, NJ, with Dr. Mark Anderson.

“The AbioCor has the potential to fill a very real void. Patients in bi-ventricular heart failure who were not candidates for a heart transplant often do not have adequate support with drug therapy or even other destination-therapy ventricular assist devices that are designed to boost only one side of the heart. Now we can continue to treat these severely ill heart failure patients,” said Dr. Laman Gray, Jr., Professor of Surgery and Director of the Division of Thoracic and Cardiovascular Surgery at the University of Louisville School of Medicine.

ABOUT ABIOMED
Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB’-EE-O-MED”) is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the IMPELLA® RECOVER® minimally invasive cardiovascular support systems under CE Mark approval. The IMPELLA products are not yet available for sale in the United States. The Company’s AbioCor® Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. For additional information please visit: www.abiomed.com.

Contacts:
Liza Heapes
ABIOMED, INC.
Media Relations
(978) 646-1668
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Daniel Sutherby
ABIOMED, INC.
Chief Financial Officer
(978) 646-1812
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of ABIOMED’s existing and new products, the Company’s progress toward commercial growth, and future opportunities. The Company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

SOURCE: Abiomed, Inc

Search in our News Channels

Search in our Online Store